WO2007143096A3 - Compounds for treating cancers - Google Patents

Compounds for treating cancers Download PDF

Info

Publication number
WO2007143096A3
WO2007143096A3 PCT/US2007/012947 US2007012947W WO2007143096A3 WO 2007143096 A3 WO2007143096 A3 WO 2007143096A3 US 2007012947 W US2007012947 W US 2007012947W WO 2007143096 A3 WO2007143096 A3 WO 2007143096A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
treating cancers
treating
mesothelioma
hepatocellular
Prior art date
Application number
PCT/US2007/012947
Other languages
French (fr)
Other versions
WO2007143096A2 (en
Inventor
Robert L Capizzi
Michel Drouin
Original Assignee
Xanthus Pharmaceuticals Inc
Robert L Capizzi
Michel Drouin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xanthus Pharmaceuticals Inc, Robert L Capizzi, Michel Drouin filed Critical Xanthus Pharmaceuticals Inc
Publication of WO2007143096A2 publication Critical patent/WO2007143096A2/en
Publication of WO2007143096A3 publication Critical patent/WO2007143096A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method of treating a patient suffering from a cancer, such as ovarian, renal, head & neck, hepatocellular, thyroid, esophageal, large bowel, pancreatic, mesothelioma, carcinoma, sarcoma and melanoma, comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. Definitions for the variables are provided herein.
PCT/US2007/012947 2006-06-02 2007-06-01 Compounds for treating cancers WO2007143096A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81024906P 2006-06-02 2006-06-02
US60/810,249 2006-06-02

Publications (2)

Publication Number Publication Date
WO2007143096A2 WO2007143096A2 (en) 2007-12-13
WO2007143096A3 true WO2007143096A3 (en) 2008-03-27

Family

ID=38582077

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/012947 WO2007143096A2 (en) 2006-06-02 2007-06-01 Compounds for treating cancers

Country Status (1)

Country Link
WO (1) WO2007143096A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2643351A1 (en) * 2010-11-24 2013-10-02 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0502668A1 (en) * 1991-03-05 1992-09-09 Btg International Limited Imidazoacridines and their antineoplastic use
WO2007092436A2 (en) * 2006-02-08 2007-08-16 Xanthus Pharmaceuticals, Inc. Compounds for treating inflammatory disorders, demyelinating disorders and cancers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0502668A1 (en) * 1991-03-05 1992-09-09 Btg International Limited Imidazoacridines and their antineoplastic use
WO2007092436A2 (en) * 2006-02-08 2007-08-16 Xanthus Pharmaceuticals, Inc. Compounds for treating inflammatory disorders, demyelinating disorders and cancers

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALAMI ET AL: "IN VITRO AND IN VIVO ACTIVITY OF C1311 AND PACLITAXEL IN THREE CANCER TUMOR MODELS", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 45, March 2004 (2004-03-01), pages 1069 - 1070, XP001536830, ISSN: 0197-016X *
ALAMI NEZHA ET AL: "Comparative in vitro analysis of C1311 activity in a panel of colorectal cell lines against standard colon cancer chemotherapies.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 45, March 2004 (2004-03-01), & 95TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; ORLANDO, FL, USA; MARCH 27 -31, 2004, pages 475, XP001536829, ISSN: 0197-016X *
KUSNIERCZYK H ET AL: "Experimental antitumor activity and toxicity of the selected triazolo- and imidazoacridinones.", ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS 1994, vol. 42, no. 5-6, 1994, pages 415 - 423, XP008085902, ISSN: 0004-069X *
MAZERSKA ZOFIA ET AL: "C-1311: Atineoplastic", DRUGS OF THE FUTURE, vol. 23, no. 7, July 1998 (1998-07-01), pages 702 - 706, XP002459524, ISSN: 0377-8282 *
SKLADANOWSKI A ET AL: "Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors.", MOLECULAR PHARMACOLOGY MAY 1996, vol. 49, no. 5, May 1996 (1996-05-01), pages 772 - 780, XP008085899, ISSN: 0026-895X *

Also Published As

Publication number Publication date
WO2007143096A2 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
UA96126C2 (en) Compound for inhibition of rhokinase activity, pharmaceutical composition comprising such a compound and method of inhibiting the activity of a rhokinase
HK1072940A1 (en) 8-hydroxy quinoline derivatives
GEP20105024B (en) Fused heterocyclic compound
WO2010017545A3 (en) Triazole compounds that modulate hsp90 activity
WO2008027542A3 (en) 5-substituted isoindoline compounds
TW200640913A (en) 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
WO2008039489A3 (en) 5-substituted quinazolinone derivatives as antitumor agents
TW200640900A (en) 1-(2h)-isoquinolone derivative
WO2010108074A3 (en) Inhibitors of pi3 kinase
MX2009006742A (en) Novel compounds.
EP1714961A4 (en) Indazole compound and pharmaceutical use thereof
WO2008019967A3 (en) Phenyl, pyridine and quinoline derivatives
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
TN2012000278A1 (en) Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors
WO2007120575A3 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
ME01335B (en) Method for reducing gastrointestinal toxicity due to the administration of tegafur
WO2009015368A3 (en) Multikinase inhibitors for use in the treatment of cancer
TNSN07294A1 (en) Treatment of metastasized tumors
WO2007103762A3 (en) Compositions and methods of use of electron transport system inhibitors
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
WO2007092436A3 (en) Compounds for treating inflammatory disorders, demyelinating disorders and cancers
WO2005077385A3 (en) Methods for treating resistant or refractory tumors
WO2008063548A3 (en) 5, 6, or 7-substituted-s- (hetero)arylisoquinolinamine derivatives as antitumor agents
WO2007143096A3 (en) Compounds for treating cancers
WO2007001839A3 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07795605

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07795605

Country of ref document: EP

Kind code of ref document: A2